Clinical Trials Logo

Clinical Trial Summary

Recent years, the European Association for the Study of the Liver-chronic liver failure (EASL-CLIF) has defined and graded acute-on-chronic liver failure (ACLF) based on CANONIC study which enrolled cirrhotic patients with acute decompensation. However, the characteristics and definitions of ACLF in non-cirrhotic patients with acute deterioration of liver function and organs injury or failure remain to be clear. As for patients who don't fulfil ACLF criteria, there might be a subgroup with high risk of progression (>25%) and a moderate 4-week mortality rate (>7%), which can be defined as "pre-ACLF", while the others are just chronic liver disease with "mere" liver injury or decompensation. This stratification system was primarily verified in a previous retrospective cohort which enrolled Hepatitis B patients only. The stratification criteria for chronic alcoholic liver disease needs to be further defined in detail. Therefore, investigators plan to prospectively recruit 3000 chronic alcoholic hospitalized patients with liver dysfunction from 24 hepatology departments in China, aiming to propose a stratified diagnostic system for chronic alcoholic patients based on organs injury. Meanwhile, risk factors of disease progression and short-term mortality will be analyzed, while characteristics and prognosis will be compared between patients with and without cirrhosis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03295812
Study type Observational
Source Nanfang Hospital of Southern Medical University
Contact Jinjun Chen
Phone 0086-18588531001
Email chjj@smu.edu.cn
Status Recruiting
Phase N/A
Start date November 16, 2017
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT00708617 - FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease N/A
Completed NCT00990639 - Effect of Candesartan in Alcoholic Liver Fibrosis Phase 1/Phase 2
Recruiting NCT04106518 - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Recruiting NCT04666402 - Integrated Diagnostics for Early Diagnosis of Liver Disease
Recruiting NCT02331745 - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Phase 4
Completed NCT01501162 - Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Phase 4
Recruiting NCT05895890 - French National MICMAF Cohort
Completed NCT04557774 - Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Recruiting NCT03267069 - Evaluating Alcohol Use in Alcoholic Liver Disease
Recruiting NCT05855031 - The Liver Care Trial N/A
Not yet recruiting NCT03503708 - Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease N/A
Completed NCT02796469 - Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis N/A
Completed NCT02140294 - Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease N/A
Recruiting NCT03209791 - Ethanol Induces Skeletal Muscle Autophagy
Recruiting NCT04400604 - Study of Alcohol-related Liver Disease in Europe
Recruiting NCT04736966 - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease Phase 1
Completed NCT03402256 - Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients N/A
Completed NCT01711125 - Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease Phase 3
Active, not recruiting NCT03863730 - Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota N/A
Not yet recruiting NCT06307964 - Intra-Hepatic Microbiota in Alcoholic Hepatitis